STOCK TITAN

Kiniksa Pharmaceuticals, Ltd. - KNSA STOCK NEWS

Welcome to our dedicated page for Kiniksa Pharmaceuticals, Ltd. news (Ticker: KNSA), a resource for investors and traders seeking the latest updates and insights on Kiniksa Pharmaceuticals, Ltd. stock.

Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) is a commercial-stage biopharmaceutical company dedicated to discovering, acquiring, developing, and commercializing therapeutic medicines for patients with debilitating diseases that have significant unmet medical needs. Headquartered in Hamilton, Bermuda, Kiniksa is at the forefront of developing immune-modulating assets aimed at addressing a spectrum of cardiovascular and autoimmune conditions.

The company’s clinical-stage product candidates include:

  • ARCALYST (rilonacept): The first and only FDA-approved therapy for recurrent pericarditis, a debilitating inflammatory cardiovascular disease. ARCALYST is also approved for cryopyrin-associated periodic syndromes (CAPS) and deficiency of IL-1 receptor antagonist (DIRA).
  • Mavrilimumab: An investigational monoclonal antibody targeting the GM-CSF receptor, currently being evaluated for its potential in treating giant cell arteritis and other rare cardiovascular diseases.
  • Vixarelimab: An investigational monoclonal antibody inhibitor of signaling through OSMRβ.
  • Abiprubart (formerly KPL-404): A humanized monoclonal antibody designed to inhibit the CD40-CD154 interaction, aimed at treating autoimmune diseases such as rheumatoid arthritis and Sjogren’s Disease.

Kiniksa’s robust pipeline is supported by significant financial strength. The company reported strong revenue growth with ARCALYST, achieving net product revenue of approximately $233.1 million in 2023, a 90% year-over-year increase. This financial performance provides a solid foundation for future investments in both commercial and clinical development projects.

Recent news highlights Kiniksa’s progress:

  • In July 2023, Kiniksa announced plans to raise its 2023 ARCALYST sales guidance to between $220 million and $230 million, citing increased prescriber adoption and patient enrollments.
  • In October 2023, the company reported third-quarter financial results and the completion of enrollment in the third cohort of the Phase 2 trial of KPL-404 in rheumatoid arthritis, with data expected in the first quarter of 2024.
  • In February 2024, Kiniksa announced its plans to initiate a Phase 2b trial of abiprubart in Sjogren’s Disease in the second half of 2024, supported by robust ARCALYST revenue growth and a strong cash position.

For more information about Kiniksa and its pipeline, visit www.kiniksa.com.

Rhea-AI Summary

Kiniksa Pharmaceuticals has begun enrolling patients in a Phase 2b clinical trial for abiprubart, a humanized anti-CD40 monoclonal antibody, aimed at treating Sjögren’s Disease, a debilitating autoimmune disorder. The trial will assess the efficacy of abiprubart administered biweekly and monthly via subcutaneous injections over a 24-week period, involving around 201 participants. The primary measure of success is the change in the EULAR Sjögren’s Syndrome Disease Activity Index (ESSDAI) compared to a placebo. The study will also include a long-term extension phase where all participants receive active treatment. Importantly, Kiniksa expects to remain cash flow positive during this development.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.86%
Tags
-
Rhea-AI Summary

Kiniksa Pharmaceuticals (Nasdaq: KNSA) announced a partnership with NHL Hall-of-Famer Henrik Lundqvist to raise awareness about recurrent pericarditis. This campaign, starting in September, aims to share experiences from the recurrent pericarditis community and provide resources for patients and caregivers. Recurrent pericarditis is characterized by severe inflammation of the pericardial tissue, leading to sharp chest pain often mistaken for a heart attack. The disease significantly impacts patients' quality of life and physical wellbeing. CEO Sanj K. Patel emphasized the need for increased disease understanding to prevent delayed diagnosis and treatment. More information can be found at whatispericarditis.com and arcalyst.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.4%
Tags
partnership
-
Rhea-AI Summary

Kiniksa Pharmaceuticals announced its sponsorship of the American Heart Association's Addressing Recurrent Pericarditis initiative on June 17, 2024. This initiative aims to enhance care for recurrent pericarditis patients through improved diagnosis and treatment practices. The program will involve healthcare champions at 15 sites to identify gaps and share best practices nationwide. The initiative aims to improve patient outcomes and quality of life through education, model sharing, and collaborative research. Key sites involved include Brigham & Women’s Hospital, Cleveland Clinic, and Mayo Clinic.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.28%
Tags
none
Rhea-AI Summary

Kiniksa Pharmaceuticals (Nasdaq: KNSA) announced its management will participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference. This event is scheduled for Tuesday, June 11, 2024, at 8:40 a.m. Eastern Time.

The presentation will be live-streamed on Kiniksa's website under the Investors & Media section. A replay will be available approximately 48 hours post-event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.02%
Tags
conferences
-
Rhea-AI Summary

Kiniksa Pharmaceuticals, (Nasdaq: KNSA) will participate in a fireside chat at the Bank of America Securities 2024 Healthcare Conference on May 14, 2024. The presentation will be available via webcast on the company's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.34%
Tags
conferences
-
Rhea-AI Summary
Kiniksa Pharmaceuticals reported strong financial results for the first quarter of 2024, with ARCALYST net product revenue reaching $78.9 million, representing an 85% year-over-year growth. The company expects ARCALYST 2024 net product revenue to increase to $370 - $390 million. Additionally, Kiniksa plans to initiate a Phase 2b trial for Abiprubart in Sjögren’s Disease in the second half of 2024. The company's current operating plan is expected to remain cash flow positive. Total revenue for the first quarter of 2024 was $79.9 million, with total operating expenses at $96.4 million. Kiniksa's net loss for the quarter was $17.7 million. The company had $213.6 million in cash, cash equivalents, and short-term investments as of March 31, 2024. Kiniksa expects 2024 ARCALYST net product revenue to be between $370 - $390 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.42%
Tags
Rhea-AI Summary
Kiniksa Pharmaceuticals, (Nasdaq: KNSA) will report its first quarter 2024 financial results on April 23, 2024. The company will host a conference call and live webcast to discuss recent portfolio execution.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.92%
Tags
conferences earnings
-
Rhea-AI Summary
Kiniksa Pharmaceuticals, announces plans to initiate Phase 2b trial in Sjogren’s Disease and presents positive data from Phase 2 Cohort 4 in rheumatoid arthritis with abiprubart. The company expects to remain cash flow positive and fully fund abiprubart development through Phase 3.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.92%
Tags
none
-
Rhea-AI Summary
Kiniksa Pharmaceuticals, Ltd. reported strong financial results for Q4 2023 and full-year 2023 with net product revenue of $71.2 million and $233.2 million, respectively. They expect ARCALYST 2024 revenue to reach $360 - $380 million, representing a 59% YoY growth. The company's cash reserves of $206.4 million are expected to fund operations until at least 2027. Positive Phase 2 data for abiprubart in rheumatoid arthritis and plans for a new indication in April 2024 were highlighted. Kiniksa also recognized positive clinical trial results for mavrilimumab and a development milestone for vixarelimab. Financially, total revenue increased to $270.3 million in 2023, with net income of $14.1 million for the full year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.54%
Tags
Rhea-AI Summary
Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) will host a conference call and live webcast on February 28, 2024, to report its Q4 and full-year 2023 financial results and recent portfolio execution. Interested individuals can access the webcast through the company's website or participate via telephone by registering. A replay will be available on Kiniksa's website post-event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.2%
Tags
conferences earnings

FAQ

What is Kiniksa Pharmaceuticals' primary focus?

Kiniksa Pharmaceuticals focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs.

What are the key products in Kiniksa's pipeline?

Key products include ARCALYST (rilonacept), Mavrilimumab, Vixarelimab, and Abiprubart (KPL-404).

What recent achievements has Kiniksa Pharmaceuticals reported?

Recent achievements include strong revenue growth with ARCALYST, increased sales guidance, and the initiation of clinical trials for abiprubart in Sjogren’s Disease.

What is ARCALYST used for?

ARCALYST is used for the treatment of recurrent pericarditis, cryopyrin-associated periodic syndromes (CAPS), and deficiency of IL-1 receptor antagonist (DIRA).

When was Kiniksa's latest financial report released?

The latest financial report was released in February 2024, covering fourth quarter and full-year 2023 results.

What is the expected revenue for ARCALYST in 2024?

Kiniksa expects ARCALYST net product revenue to be between $370 million and $390 million in 2024.

What is abiprubart (KPL-404) targeting?

Abiprubart targets the CD40-CD154 interaction, aiming to address multiple autoimmune disease pathologies.

What are some of the conditions Kiniksa is targeting with its therapies?

Conditions include recurrent pericarditis, rheumatoid arthritis, Sjogren’s Disease, and other cardiovascular and autoimmune diseases.

Where can I find more information about Kiniksa Pharmaceuticals?

More information can be found on their official website at www.kiniksa.com.

Who should be contacted for investor and media inquiries?

Rachel Frank can be contacted at (339) 970-9437 or rfrank@kiniksa.com for investor and media inquiries.

Kiniksa Pharmaceuticals, Ltd.

Nasdaq:KNSA

KNSA Rankings

KNSA Stock Data

1.51B
40.45M
6.57%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
HAMILTON